US › Healthcare

Allarity Therapeutics Inc (ALLR)

US · Healthcare · Biotechnology

$1.31+3.15%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$25,000
Net profit
$-2.8M
Profit YoY
-0.7%
EPS
$-0.17
EPS estimate
$-0.22
Net margin
-11,000.0%

EPS came in at -0.17 against a street estimate of -0.22 — a beat of 22.7%.

Key statistics

Market cap
$19.3M
Forward P/E
0.0
P/B
2.78
Book value
$0.44
EPS (TTM)
$-0.70
52-week high
$2.06
52-week low
$0.77
50-day MA
$1.38
200-day MA
$1.23
Beta
0.53

Analyst view

Analysts rate Allarity Therapeutics Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $10.25.

Shareholding

Insiders
4.19%
Institutions
5.97%

Largest institutional holders

FundStake
Renaissance Technologies Corp1.43%
Geode Capital Management, LLC1.20%
Vanguard Capital Management, LLC1.08%
State Street Corp0.86%
Vanguard Fiduciary Trust Co0.47%
Northern Trust Corp0.30%
XTX Topco Ltd0.18%
Two Sigma Investments LLC0.17%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Allarity Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.